Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor before-and-after study in cystic fibrosis patients with class III CFTR mutations
NL-OMON26309Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivacaftor in cystic fibrosis (CF), sponsored by University Medical Center Utrecht. Primary endpoint: Change in sweat chloride concentration. Started May 2015; status: active, not recruiting.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON26309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26309.